InvestorsHub Logo
Followers 21
Posts 2213
Boards Moderated 0
Alias Born 04/14/2007

Re: diddobuyer post# 6020

Tuesday, 03/04/2014 12:58:56 PM

Tuesday, March 04, 2014 12:58:56 PM

Post# of 9287
Navidea apparent low revenues and "high" cash burn rate are due to:

Lymphoseek approval for a limited sector of its potential users. They are seeking to expand the usage as evidence by their recent submission to the FDA.

They also had essentially no sales force when first approved.

NEW Drugs: Navidea has several drugs in phase II/III trials. These trials take large sums of money and time with little or no guarantee of success.

Sometimes the stock market seems like sailing a wooden ship into a sea of burning oil.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NAVB News